Expert opinion on pharmacotherapy of narcolepsy

Bibliography

• American Academy of Sleep Medicine; European Sleep Research Society. International Classification of Sleep Disorders, 2nd edition. Diagnostic and coding manual. American Academy of Sleep Medicine Westchester, IL; 2005
   Google Scholar
• Hublin C, Kaprio J, Partinen M, The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994;11:709-16
   Google Scholar
• Ohayon MM, Priest RG, Zulley J, Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002;58:1826-33
   PubMed Web of Science ®Google Scholar
• Silber MH, Krahn LE, Olson EJ, The epidemiology of narcolepsy in Olmsted county, Minnesota: a population-based study. Sleep 2002;25:197-202
   PubMed Web of Science ®Google Scholar
• Wing YK, Li RH, Lam CW, The prevalence of narcolepsy among Chinese in Hong-Kong. Ann Neurol 2002;51:578-84
   PubMed Web of Science ®Google Scholar
• Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9:269-310
   PubMed Web of Science ®Google Scholar
• Overeem S, Mignot E, Van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105
   PubMed Web of Science ®Google Scholar
• Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000;4:57-99
   PubMed Web of Science ®Google Scholar
• Chabas D, Taheri S, Renier C, Mignot E. The genetics of narcolepsy. Annu Rev Genomics Hum Genet 2003;4:459-83
   PubMed Web of Science ®Google Scholar
• Ripley B, Fujiki N, Okura M, Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001;8:525-34
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin(orexin) receptor 2 gene. Cell 1999;98:365-76
   PubMed Web of Science ®Google Scholar
• Peyron C, Faraco J, Rogers W, A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2000;50:381-8
   Web of Science ®Google Scholar
• Mignot E, Lin X, Arrigoni J, DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep 1994;17(Suppl 8):60-7
   Web of Science ®Google Scholar
• Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50(2 Suppl 1):16-22
   Web of Science ®Google Scholar
• Mignot E, Hayduk R, Black J, HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-20
   PubMed Web of Science ®Google Scholar
• Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007;8:373-99
   PubMed Web of Science ®Google Scholar
• Littner M, Johnson SF, McCall WV, Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24:451-66
   PubMed Web of Science ®Google Scholar
• Physician's Desk Reference. Montvale, NJ: Medical Economics, 2005
   Google Scholar
• US Food and Drug Administration (FDA). InfoSheets; 2005. Available from: http://www.fda.gov/cder/drug/InforSheets/HCP/pemolineHCP.pdf [Last accessed 2 Feb 2010]
   Google Scholar
• Mitler MM, Aldrich MS, Koob GF, Zarconne VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17:352-71
   PubMed Web of Science ®Google Scholar
• Kuczenski R, Segal DS. Effects of methyphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:2032-7. Erratum in J Neurochem 1997;69:1332
   PubMed Web of Science ®Google Scholar
• Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005;28:754-63
   PubMed Web of Science ®Google Scholar
• Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat 2008;4:557-66
   PubMedGoogle Scholar
• Wisor JP, Nishino S, Sora I, Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-94
   PubMed Web of Science ®Google Scholar
• Qu WM, Huang ZL, Xu XH, Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008;28:8462-9
   PubMed Web of Science ®Google Scholar
• Scammell TE, Estabrooke IV, McCarthy MT, Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8
   PubMed Web of Science ®Google Scholar
• Ferraro L, Tanganelli S, O'Conoor W, The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996;306:33-9
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-75
   PubMed Web of Science ®Google Scholar
• Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000;1:109-16
   PubMed Web of Science ®Google Scholar
• Billiard M, Nicolet A, Dauvilliers Y, Modafinil: the European experience. In: Bassetti C, Billiard M, Mignot E, editors, Narcolepsy and hyperosmnia. Informa Healthcare, New York; 2007. p. 561-9
   Google Scholar
• Thorpy MJ, Black J, Erman MK. The safety profile of modafinil in disorders of sleep and wakefulness. Neurology 2004;62(Suppl 5):A56-7
   Google Scholar
• Broughton RJ, Fleming JAE, George CFP, Randomized, double-blind placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-51
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
   PubMed Web of Science ®Google Scholar
• Beuersterien KM, Rogers AAE, Walsleben JA, Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-65
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-75
   PubMed Web of Science ®Google Scholar
• Billiard M, Besset A, Montplaisir J, Modafinil: a double-blind multicenter study. Sleep 1994;17(Suppl):107-12
   Google Scholar
• Erman MK, Hirshowitz M, Schwartz JR. Modafinil improves wakefulness and clinical condition in obstructive sleep apnea. Presented at the 70th Annual Meeting of the American College of Chest Physicians; 27 October 2004; Seattle, WA, USA
   Google Scholar
• Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003;4:579-82
   PubMed Web of Science ®Google Scholar
• Harsh JR, Hayduk R, Rosenberg R, The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-74
   PubMed Web of Science ®Google Scholar
• Bonaventure P, Letavic M, Dugovic C. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 2007;73:1084-96
   PubMed Web of Science ®Google Scholar
• Jenner P, Zeng B-Y, Smith LA, Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset. Exp Brain Res 2000;133:178-88
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-11
   PubMed Web of Science ®Google Scholar
• Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004;42:185-95
   PubMed Web of Science ®Google Scholar
• Kushida CA. Countermeasures for sleep loss and sleep deprivation. Curr Treat Options Neurol 2006;8:361-6
   PubMedGoogle Scholar
• De Valck E, De Groot E, Cluydts R. Effects of slow-release caffeine and a nap on driving simulator performance after partial sleep deprivation. Percept Mot Skills 2003;96:67-78
   PubMed Web of Science ®Google Scholar
• Walsh JK, Muehlbach MJ, Schweitzer PK. Hypnotics and caffeine as countermeasures for shiftwork-related sleepiness and sleep disturbance. J Sleep Res 1995;4:80-3
   PubMed Web of Science ®Google Scholar
• Martinez-Rodriguez J, Iranzo A, Santamaria J, Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 2002;17:113-16
   PubMed Web of Science ®Google Scholar
• Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704-6
   PubMedGoogle Scholar
• Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat 2008:4:557-66
   PubMedGoogle Scholar
• Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78
   PubMed Web of Science ®Google Scholar
• Plazzi G, Montagna P, Provini F, Treatment of narcolepsy with cataplexy. Lancet 2007;369:1081
   PubMed Web of Science ®Google Scholar
• Izzi F, Placidi F, Marciani MG, Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases. Sleep Med 2009;10:153-4
   PubMed Web of Science ®Google Scholar
• Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep 2005;28:1189
   PubMed Web of Science ®Google Scholar
• Terzano MG, Mancia D, Salati MR, The cyclic alternating pattern as a physiological component of normal NREM sleep. Sleep 1985;8:137-45
   PubMed Web of Science ®Google Scholar
• Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. Rev Psychopharmacol (Berl) 1996;126:1-16
   PubMed Web of Science ®Google Scholar
• Terzano M, Smerieri A, Del Felice A, Cyclic alternating pattern (CAP) alterations in narcolepsy. Sleep Med 2006;7:619-26
   PubMed Web of Science ®Google Scholar
• Maitre M, Humbert JP, Kemmel V, A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse [in French]. Med Sci (Paris) 2005;21:284-9
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study Group. A randomized, double blind placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study Group. A 12-month open-label multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31-5
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23
   PubMed Web of Science ®Google Scholar
• Black J, Ristanovic R, Mamelak M, Montplaisir J. Dose response effects of sodium oxybate on polysomnographic (PSG) measures in narcolepsy patients; preliminary findings. Sleep 2001;24(Suppl):A321
   PubMed Web of Science ®Google Scholar
• Hayduk R, Mitler MM. Sodium oxybate therapy improves the quality of life of narcolepsy patients. Sleep 2001;24(Suppl):A326
   Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;2:939-46
   Google Scholar
• Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind placebo-controlled study in 228 patients. Sleep Med 2005;6:415-21
   PubMed Web of Science ®Google Scholar
• Jazz pharmaceuticals. Xyrem (sodium oxybate) oral solution. Available at: http://jazzph.isat-tech.com/media/PI.pdf [Last accessed 2 February 2010]
   Google Scholar
• Soares CN, Murray BJ. Sleep disorders in women: clinical evidence and treatment strategies. Psychiatr Clin North Am 2006;29:1095-113
   PubMed Web of Science ®Google Scholar
• Manconi M, Govoni V, De Vito A, Restless legs syndrome and pregnancy. Neurology 2004;63:1065-9
   PubMed Web of Science ®Google Scholar
• Edwards N, Middleton PG, Blyton DM, Sullivan CE. Sleep disordered breathing and pregnancy. Thorax 2002;57:555-8
   PubMed Web of Science ®Google Scholar
• Kent JM. SnaRIs, NaSSAs, and NARIs: new agents for the treatment of depression. Lancet 2000;355:911-18, Erratum in: Lancet 2000;355:2000
   PubMed Web of Science ®Google Scholar
• Beer B, Stark J, Krieter P, DOV 216,303, a ‘triple’ reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004;44:1360-7
   PubMed Web of Science ®Google Scholar
• Nishino S, Arrigoni J, Shelton J, Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-8
   PubMed Web of Science ®Google Scholar
• Riehl J, Honda K, Kwan M, Chronic oral administration of CG-3703, a thyrotropin-releasing hormone analog, increase wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000;23:34-45
   PubMed Web of Science ®Google Scholar
• Nicoll RA. Excitatory action of TRH on spinal motoneurons. Nature 1977;265:242-3
   PubMed Web of Science ®Google Scholar
• González JA, Horjales-Araujo E, Fugger L, Stimulation of orexin/hypocretin neurons by thyrotropin-releasing hormone. J Physiol 2009;587:1179-86
   PubMed Web of Science ®Google Scholar
• Griffiths EC, Bennett GW. Clinical applications of thyrotropin-releasing hormone. Clin Sci 1987;73:449-57
   Web of Science ®Google Scholar
• Vogel HP, Benkert O, Illig R, Psychoendocrinological and therapeutic effects of TRH in depression. Acta Psychiatr Scand 1977;56:223-32
   PubMed Web of Science ®Google Scholar
• Bunevicius R, Matulevicus V. Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study. Psychoneuroendocrinology 1993;18:445-9
   PubMed Web of Science ®Google Scholar
• Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000;4:471-503
   PubMed Web of Science ®Google Scholar
• Shiba T, Fujiki N, Wisor JP, Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2000;27(Suppl):SA241-2
   Google Scholar
• Tedford CE, Edgar DM, Seidel WF, Effects of a novel, selective and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy. Abstr Soc Neurosci 1999;25:1134
   Google Scholar
• Lin JS, Dauvilliers Y, Arnulf I, An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients. Neurobiol Dis 2008;30:74-83
   PubMed Web of Science ®Google Scholar
• Silber MH, Black JL, Krahn LE, Autoimmune studies in narcolepsy. In: Bassetti C, Billiard M, Mignot E, editors, Narcolepsy and Hypersomnia. Informa Healthcare, New York; 2007. p. 451-7
   Google Scholar
• Aran A, Lin L, Nevsimalova S, Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009;32:979-83
   PubMed Web of Science ®Google Scholar
• Lecendreux M, Maret S, Bassetti C, Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12:347-8
   PubMed Web of Science ®Google Scholar
• Hect M, Ling L, Kushida C, Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003;26:809-10
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, River F, IVIG treatment in narcolepsy: report on two new cases. J Sleep Res 2004;13(Suppl 1):167
   Google Scholar
• Zuberi SM, Mignot E, Ling L, MacArthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res 2004;13(Suppl 1):828
   Google Scholar
• Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58:489-90
   PubMed Web of Science ®Google Scholar
• Peyron C, Faraco J, Rogers W, A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
   PubMed Web of Science ®Google Scholar
• Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999;289:219-23
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Fujiki N, Maki RA, Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett 2003;346:182-6
   PubMed Web of Science ®Google Scholar
• Fujiki N, Ripley B, Yoshida Y, Effects of IV and ICV hpocretin-1 (orexin-A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003;6:953-9
   Google Scholar
• John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000;3:23-8
   PubMedGoogle Scholar
• Hanson LR, Martinez PM, Taheri S, Intranasal administration of hypocretin 1 (Orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Technol 2004;4:66-71
   Google Scholar
• Hallschmid M, Benedict C, Born J, Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 2004;83:55-64
   PubMed Web of Science ®Google Scholar
• Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27:14239-47
   PubMed Web of Science ®Google Scholar
• Croston GE, Olsson R, Currier EA, Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one(AC-7954). J Med Chem 2002;45:4950-3
   PubMed Web of Science ®Google Scholar
• Zaveri N. Peptide and nonpeptide ligands for the nociceptine/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 2003;73:663-78
   PubMed Web of Science ®Google Scholar
• Saar K, Mazarati AM, Mahlapuu R, Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 2002;99:7136-41
   PubMed Web of Science ®Google Scholar
• Arias-Carrion O, Murillo-Rodriguez E, Xu M, Transplant of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004:27:1465-70
   PubMed Web of Science ®Google Scholar
• Huang YS, Guilleminault C. Narcolepsy: action of two gamma aminobutyric acid type B agonists, Baclofen and sodium oxybate. Pediatr Neurol 2009;41:9-16
   PubMed Web of Science ®Google Scholar